4
S. Kasatkina et al. / Tetrahedron Letters 60 (2019) 151088
Acknowledgment
This work was supported by the Russian Science Foundation,
project # 19-13-00290.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
MOL files and InChiKeys of the most important compounds
described in this article.
References
(b) S. Collins, S. Bartlett, F. Nie, H.F. Sore, D.R. Spring, Synthesis 48 (2016) 1457–
(c) K. Torikai, R. Koga, X. Liu, K. Umehara, T. Kitano, K. Watanabe, T. Oishi, H.
Noguchi, Y. Shimohigashi, Bioorg. Med. Chem. 25 (2017) 5216–5237, https://
(d) S.L. Kidd, Th.J. Osberger, N. Mateu, H.F. Sore, D.R. Spring, Front. Chem. 6
(f) X. Jiang, X. Hao, L. Jing, G. Wu, D. Kang, X. Liu, P. Zhan, Expert Opin. Drug
[2] (a) S. Dandapani, L.A. Marcaurelle, Curr. Opin. Chem. Biol. 14 (2010) 362–370,
(b) S. Yi, B.V. Varun, Yo Choi, S.B. Park, Front. Chem. 6 (2018) 507, https://doi.
[3] (a) S. Rosenzweig-Lipson, J. Zhang, H. Mazandarani, B.L. Harrison, A. Sabb, J.
Sabalski, G. Stack, G. Welmaker, J.E. Barrett, J. Dunlop, Brain Res. 1073–1074
(b) A.N. Maslivets, S.O. Kasatkina, E.E. Stepanova, R.R. Makhmudov. RU Patent 2
676 682, 2019.;
(c) M.A. Martins Alho, Y. Marrero-Ponce, S.J. Barigye, A. Meneses-Marcel, Y.
Machado Tugores, A. Montero-Torres, A. Gómez-Barrio, J.J. Nogal, R.N. García-
Sánchez, M.C. Vega, M. Rolón, A.R. Martínez-Fernández, J.A. Escario, F. Pérez-
Giménez, R. Garcia-Domenech, N. Rivera, R. Mondragón, M. Mondragón, F.
Ibarra-Velarde, A. Lopez-Arencibia, C. Martín-Navarro, J. Lorenzo-Morales, M.G.
Cabrera-Serra, J. Piñero, J. Tytgat, R. Chicharro, V.J. Arán, Bioorg. Med. Chem. 22
(d) X.F. Wang, F. Guan, E. Ohkoshi, W. Guo, L. Wang, D.Q. Zhu, S.B. Wang, L.T.
Wang, E. Hamel, D. Yang, L. Li, K. Qian, S.L. Morris-Natschke, S. Yuan, K.H. Lee, L.
[4] (a) N.Yu. Lisovenko, A.N. Maslivets, Z.G. Aliev, Chem. Heterocycl. Compd. 39
(b) N.Yu. Lisovenko, A.N. Maslivets, Chem. Heterocycl. Compd. 40 (2004) 247–
(c) N.Yu. Lisovenko, A.N. Maslivets, Z.G. Aliev, Russ. J. Org. Chem. 40 (2004)
(d) N.Yu. Lisovenko, A.N. Maslivets, Z.G. Aliev, Russ. J. Org. Chem. 43 (2007)
Scheme 4. Plausible pathway for the reaction of acyl(quinoxalinyl)ketenes 2 with
carbodiimides 4.
substituent. Conversely, alkoxycarbonyl/pivaloyl bearing zwitteri-
ons A underwent intramolecular cyclization at the enamino motif
because its enolized resonance structure B is unfavorable.
In conclusion, we have developed
a divergent synthetic
methodology towards two distinct quinoxaline-based heterocycles
based on the substituent controlled cycloaddition reaction of acyl
(quinoxalinyl)ketenes with carbodiimides. Acyl(quinoxalinyl)kete-
nes were generated in situ as a result of the thermal decarbonyla-
tion reaction of pyrroloquinoxalinetriones. In the case of aroyl
substituted acyl(quinoxalinyl)ketenes, the O@C@CAC@O system
underwent the cycloaddition reaction, and (quinoxalin-2-yl)-1,3-
oxazines were obtained as the sole products. Involvement of
alkoxycarbonyl or pivaloyl substituted acyl(quinoxalinyl)ketenes
led to the exclusive formation of pyrimido[1,6-a]quinoxalines,
the products of cycloaddition at the O@C@CAC@N system. Our
study is the first example of a divergent cycloaddition reaction of
acyl(quinoxalinyl)ketenes resulting in either (quinoxalin-2-yl)-
1,3-oxazines or pyrimido[1,6-a]quinoxalines formation. The pro-
posed strategy provides facile access to a library of skeletally
diverse pharmaceutically interesting quinoxaline-based heterocy-
cles from inexpensive reagents.
(e) D.D. Nekrasov, A.S. Obukhova, N.Yu. Lisovenko, A.E. Roubtsov, Chem.
(f) N.Yu. Lisovenko, D.D. Nekrasov, V.I. Karmanov, Chem. Heterocycl. Compd. 48
[5] S.O. Kasatkina, E.E. Stepanova, M.V. Dmitriev, I.G. Mokrushin, A.N. Maslivets,
[6] (a) A.N. Maslivets, K.S. Bozdyreva, I.V. Smirnova, I.A. Tolmacheva, I.V.
(b) A.N. Maslivets, Z.G. Aliev, O.P. Krasnykh, O.V. Golovnina, L.O. Atovmyan,
(c) K.S. Bozdyreva, I.V. Smirnova, A.N. Maslivets, Russ. J. Org. Chem. 41 (2005)
[7] E.E. Stepanova, S.O. Kasatkina, M.V. Dmitriev, A.N. Maslivets, Synthesis 50